{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-290244","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2022-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.056533+00:00","generated_at":"2026-06-21T14:07:39.156352+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Graybug to merge with CalciMedica; combined company focused on Auxora for inflammatory diseases","bullets":["Graybug holders to own ~29% of combined co; CalciMedica holders ~71% (based on $40M and $100M valuations).","Combined co expected to have ~$35M cash at close, with runway into H2 2024; includes ~$10.3M private placement.","Auxora Phase 2b AP data expected H2 2023; Phase 1/2 AAP data H1 2023; potential accelerated approval path.","Rachel Leheny (CalciMedica CEO) to lead combined co; board 5 CalciMedica / 2 Graybug; close expected Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-290244","json":"https://secwatch.observer/filing/0001193125-22-290244.json","markdown":"https://secwatch.observer/filing/0001193125-22-290244.md","text":"https://secwatch.observer/filing/0001193125-22-290244.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000119312522290244/0001193125-22-290244-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000119312522290244/d403773d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T14:07:39.156352+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51e28ce4bc3217d76d219b7f5bdb79e21747c298","claim":"CalciMedica, Inc. entered into Agreement and Plan of Merger and Reorganization with CalciMedica, Inc. (effective 2022-11-21).","evidence_excerpt":"On November 21, 2022, Graybug Vision, Inc., a Delaware corporation (“ Graybug ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with CalciMedica, Inc., a Delaware corporation (“ CalciMedica ”), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for serious inflammatory diseases with high unmet need, and Camaro Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Graybug (“ Merger Sub ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312522290244/0001193125-22-290244-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"CalciMedica, Inc."},{"label":"Effective","value":"2022-11-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}